Loading...

Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317301 25 µg 30 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg 55 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  2. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  3. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  4. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  5. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  6. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  7. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  8. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  9. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  10. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  11. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  12. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  13. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  14. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  15. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  16. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  17. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  18. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  19. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  20. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  21. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  22. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  23. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  24. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  25. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  26. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  27. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  28. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  29. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  30. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  31. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  32. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  33. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  34. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  35. Willimsky G, et al. 2021. Elife. 10:. PubMed
  36. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  37. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  38. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  39. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  40. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  41. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  42. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  43. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  44. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  45. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  46. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  47. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  48. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  49. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  50. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  51. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  52. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  53. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  54. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  55. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  56. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  57. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  58. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  59. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  60. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  61. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  62. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  63. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  64. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  65. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  66. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  67. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  68. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  69. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  70. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  71. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  72. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  73. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  74. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  75. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  76. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  77. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  78. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  79. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  80. Henrick BM, et al. 2021. Cell. . PubMed
  81. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  82. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  83. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  84. Ardain A, et al. 2019. Nature. 570:528. PubMed
  85. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  86. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  87. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  88. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  89. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  90. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  91. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  92. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  93. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  94. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  95. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  96. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  97. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  98. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  99. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  100. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  101. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  102. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  103. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  104. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  105. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  106. Naranbhai V, et al. 2022. Cell. . PubMed
  107. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  108. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  109. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  110. He Y, et al. 2021. eLife. 10:00. PubMed
  111. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  112. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  113. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  114. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  115. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  116. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  117. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  118. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  119. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  120. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD3
Specificity Alt (DOES NOT SHOW ON TDS):
CD3
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC-F
UniProt
View information about CD3 on UniProt.org
Go To Top Version: 2    Revision Date: 06.12.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account